Invest In Biomed is a unique Eurobiomed program that helps innovative healthcare companies consolidate their fund-raising approach and tools, and introduces them to specialized investors in the sector. To mark the launch of the 10e edition of this program, we give the floor to entrepreneurs who have benefited from it.
Entrepreneurs from the scientific and academic worlds, Philippe Andres, Janusz Czernielewski and Gareth Winckle have benefited from Eurobiomed's Invest In Biomed program to structure their financing strategy. Their company Tarian Pharma, which develops solutions to combat the cutaneous side-effects of cancer treatments, successfully raised €4 million in two successive rounds.
How has the Invest In Biomed program helped you adapt your pitch to investors?
Janusz Czernielewski: Coming from the scientific and academic world, we tended to be too technical in our presentations. The support we received enabled us to learn the vocabulary and codes of the financial world.
We realized that an overly scientific approach could quickly lose the attention of investors. The Eurobiomed team guided us in presenting our innovation in a more accessible way, without losing any of its substance.
How did you approach the notion of risk with investors?
Philippe Andres: There was a big gap between our perception of risk and that of financiers. For the latter, a project in the pre-clinical phase represents a major risk. While we were convinced of the soundness of our scientific data, this message was difficult for them to hear.
The program helped us to better understand this perception and adapt our communication accordingly.
What adjustments have you made to your fundraising strategy?
Gareth Winckle: Initially, we were aiming for an ambitious round to cover a large part of our program. After discussions, we realized that it would be better to 'split up' our approach.
We revised our target for the first round to around 2 million euros, an amount better suited to our stage of development. This strategy paid off, as we succeeded in convincing our investors, before raising a second round a year later.
SIMILAR ARTICLES :
Amaury Ciurana (REEV): "The Invest In Biomed program offered us a privileged framework for building relationships of trust with our investors".
Arnaud Debains and Sandrine Isz (BOYDSense): "Invest In Biomed helped us tell our story better".
